Raphael Landovitz

Raphael Landovitz

 

Dr. Raphael Landovitz, the principal investor for HPTN 083, is a professor of medicine at the UCLA Center for Clinical AIDS Research & Education in Los Angeles. His research agenda focuses on optimizing the use of antiretroviral medications for HIV treatment and HIV prevention. In addition, Dr. Landovitz has led combination prevention intervention studies and projects using post-exposure (PEP) and pre-exposure (PrEP) strategies for men who have sex with men. He was awarded the HIVMA HIV Research Award in 2017 and the AIDS Clinical Trials Group’s John Carey Young Investigator Award in 2010.